Redefining Clinical Lipid Lowering

Practice in Post-ACS Patients A Case-based Approach

Saturday,  11th  February 2017

1.00pm – 2.00pm The Auditorium, Brisbane Convention Centre

professor-patrick-m-moriarty-mdProfessor Patrick M. Moriarty,  MD
Professor, Department of Internal Medicine Director, Division of Clinical Pharmacology and Atherosclerosis/Lipid Apheresis Center University of Kansas Medical Center, Kansas City, Kansas.

Patrick M. Moriarty, MD is a Professor of Medicine at The University of Kansas Medical Center in Kansas City, Kansas. He is the Director of Clinical Pharmacology and the Atherosclerosis/ Lipid- Apheresis Center. He earned his Doctorate in Medicine and Surgery at the University of   Rome School of Medicine and Surgery in Italy and completed his residency in Internal Medicine and training in Clinical Pharmacology at the University of Kansas Medical Center. Dr. Moriarty is a fellow of the American College of Physicians, the American College of Cardiology, and the National Lipid Association. He is the past president of the International Society for Apheresis and serves as a manuscript reviewer for multiple scientific journals and is the associate editor for The Journal of Clinical Apheresis and Clinical Lipidology. He has authored or co-authored over 100 articles, abstracts and chapters in peer review journals. His research activities include atherosclerosis, Lipid-Apheresis, vascular inflammation and hemo-rheology. He has participated in numerous clinical trials related to dyslipidemia, obesity, hypertension, and diabetes. His clinical activities involve the treatment and diagnosis of atherosclerosis and cardiovascular disease. The University of Kansas Lipid-Apheresis Center is one of the largest centers in North America for the treatment of Familial Hypercholesterolemia.

professor-peter-p-toth-md-phd-faafp-fnla-fahaProfessor Peter P Toth, MD, PhD, FAAFP, FNLA, FAHA
Director of Preventative Cardiology CGH Medical Center, Sterling, IL and Professor of Clinical Family and Community Medicine University of Illinois College of Medicine, Peoria, IL

Peter P Toth, MD, PhD, FAAFP, FNLA, FAHA, is Director of Preventive Cardiology at CGH Medical Center in Sterling, IL, and Professor of Clinical Family and Community Medicine at the University Of Illinois College Of Medicine in Peoria. He received his medical degree from Wayne State University School of Medicine in Detroit, MI, and PhD in Biochemistry from Michigan State University in East Lansing. Dr Toth completed his residency training in Family Medicine at the University of Iowa Hospitals and Clinics. Dr Toth has authored and coauthored over 220 publications in medical and scientific journals and textbooks. He is Editor-in-Chief of theYear in Lipid Disorders, Associate Editor for the Year Book of Endocrinology, and Coeditor of the textbook, Comprehensive Management of High Risk Cardiovascular Patients. Dr Toth has lectured on many topics in cardiovascular medicine throughout the world. Additionally, he is a member of the American College of Cardiology Foundation Council on Cardiovascular Disease Prevention and American Heart Association’s Council on Lipoproteins, Lipid Metabolism, and Thrombosis. Dr Toth is also a member of Alpha Omega Alpha and Sigma Xi, and is past President of the National Lipid Association. He serves as Vice President of the American Board of Clinical Lipidology and member of the board of the American Society of Preventive Cardiology.

aprofessor-karam-kostnerA/Professor Karam Kostner, MD, PhD, FRACP, FCSANZ
Director of Cardiology at the Mater Hospital Brisbane and Associate Professor of Medicine, University of Queensland.

A/Professor Karam Kostner is a general cardiologist and lipidologist with an interest in imaging and has extensive clinical and research experience in lipid management and primary prevention of CVD. He runs a large public and private Lipid and Primary Prevention Clinic at the Mater Hospital in Brisbane. He is a past President of the CSANZ Qld branch. He is CV section editor of the European Journal of Clinical Investigation and reviewer for many other journals. He has organised many national and international conferences and is the chair of the World Congress of Clinical Lipidology which will be held in Brisbane in February 2017. Dr Kostner has more than 100 publications and is a grant reviewer for NHMRC and several european grant agencies.

Practice in Post-ACS Patients A Case-based Approach

Saturday,  11th  February 2017

1.00pm – 2.00pm The Auditorium, Brisbane Convention Centre


1.00 – 1.10pm

Introduction  and  Redefining  LDL-C  targets   post-ACS  in Australia

A/Professor Karam Kostner

1.10 – 1.30pm

Case 1: ACS patient unable to   reach target

Case 2:  Diabesity patient  

Professor Peter Toth

1.30 – 1.50pm

Case 3:  FH patient
Case 4: Statin intolerant patient

Professor Patrick Moriarty

1.50 – 2.00pm Panel  discussion  &  closing remarks

A/Professor Karam Kostner, Professor Peter Toth & Professor Patrick Moriarty

2.00pm Meeting Close

Persons accompanying an invited Healthcare Professional will not be paid for or subsidised by the Sponsors and the Sponsors will not accept any fees or charges for accompanying persons. Any charges levied or incurred, including those for accommodation, travel and/or meals for accompanying persons, must be paid directly to the third party. Accompanying persons are not permitted to attend any part of the educational sessions or meals organised by the Sponsors.

SANOFI PRIVACY STATEMENT: Your personal information will be used to process this invitation. Sanofi will not disclose your personal information to anyone other than contractors who provide services to us or unless compelled or permitted by law to do so. If you want to know more about our privacy policy and procedures please refer to our website au. If you would like to update or amend your details or be excluded from future events, please contact our Privacy Officer at

Sanofi and Regeneron are committed to providing resources to better understand cholesterol management and to research the unmet needs of patients with poorly controlled LDL-C. sanofi-aventis australia pty ltd trading as Sanofi, ABN 31 008 558 807, Talavera Corporate Centre, 12-24 Talavera Road, Macquarie Park NSW 2113. November 2016.